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OBJECTIVES: Aromatase inhibitors are the first-choice drugs for the treatment of hormone sensitive breast
cancer. However, in addition to the scarcity of studies, there are controversies about their effects on vaginal
epithelial cell proliferation in rats, especially those in persistent estrus.
METHODS: To investigate vaginal epithelial cell proliferation by Ki-67 antigen expression, persistent estrus was
induced in 42 randomly selected rats. These rats were randomly divided into 2 groups: group I (control, n=21),
which received 0.1 mL of propylene glycol (vehicle) daily, and group II (experimental, n=21), which received
0.5 mg/kg or 0.125 mg/day of anastrozole diluted with 0.1 mL of propylene glycol.
RESULTS: Light microscopy showed a higher concentration of cells with brown Ki-67 stained nuclei in the control
compared to the experimental group. The mean percentage of Ki-67 stained nuclei per 500 cells in the vaginal
epithelium was 68.64±2.64 and 30.46±2.00 [mean±standard error of the mean (SEM)] in the control and
experimental groups, respectively (po0.003).
CONCLUSION: This study showed that anastrozole, at the dose and treatment duration selected, significantly
decreased cell proliferation in the vaginal mucosa of the rats in persistent estrus.
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’ INTRODUCTION
Vaginal atrophy and hormone-sensitive breast cancer are
common conditions in postmenopausal women, for which
tamoxifen is the standard endocrine therapy; however,
although tamoxifen may have trophic effects on the vaginal
epithelium, severe adverse effects such as endometrial cancer
lead to the search of alternative endocrine therapies (1).
Third-generation aromatase inhibitors, such as anastrozole,
letrozole, and exemestane, have become the first-choice drug
for endocrine treatment of hormone-sensitive breast cancer in
postmenopausal women. In particular, anastrozole has been
emphasized as the endocrine therapy of choice in post-
menopausal women (2). These drugs are associated with
greater efficacy in breast cancer and improved general
tolerability compared to tamoxifen (3). Furthermore, tamox-
ifen is associated with undesirable adverse effects, particu-
larly, the increased incidence of endometrial hyperplasia and
even endometrial cancer, as well as cataracts, thromboembo-
lism, and cerebrovascular events (4).
The use of anastrozole for long periods does not show any
effect on the levels of steroid hormones, such as cortisol,
aldosterone, androstenedione, and 16-hydroxyprogesterone,
confirming anastrozole’s high selectivity in inhibiting aro-
matase without interfering with other adrenal steroidogen-
esis pathways (5-7). Anastrozole also does not affect the
synthesis of gonadotropins and steroids that are dependent
on the hypothalamic-pituitary-ovarian axis (8-10). Studies
on the effects of anastrozole on the vaginal epithelium in
women present ethical limitations. Hence the need for
experimental animal models exists, even though there are
limitations in regards to the extrapolation of results from
animals to humans (11-13). In terms of vaginal epithelial
tissue and sensitivity to therapy, the rat animal model would
be most similar to humans (14).
The persistent estrus female rat is a model that is under
constant estrogenic stimulation, mimicking polycystic ovar-
ian syndrome. Therefore this model is interesting and usefulDOI: 10.6061/clinics/2020/e1643
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to study the effects of hormonal drugs (15-16), such as
anastrozole, which inhibit estrogen synthesis. Nery-Aguiar
et al. (1) showed that tamoxifen significantly increased cell
proliferation in the vaginal mucosa of castrated rats, as
evaluated by means of Ki-67 protein expression. On the other
hand, the effects of anastrozole in the vaginal epithelium
of premenopausal rats are unclear. Meanwhile, among the
aromatase inhibitors, letrozole significantly reduced cell
proliferation in the endometrial and vaginal epithelia of
female rats (17). However, Sadlonova et al. (18) administered
anastrozole in the diet of rats for 15 weeks and did not show
atrophy of the endometrial and vaginal epithelia. Although
these were experimental studies using animal models, they
lead to further interest for studies aimed at the clinical
application of aromatase inhibitors in women with breast
cancer and vaginal atrophy. Considering the controversies
and, to the best of our knowledge, the scarcity of studies of
the effects of anastrozole on the vaginal epithelium of rats in
persistent estrus, the present study was designed.
’ MATERIALS AND METHODS
Animals
This study was approved by the Animal Experimentation
Ethics Committee of the Federal University of Piauí (UFPI)
and conducted according to the ethical principles establi-
shed by the Brazilian College of Animal Experimentation
(COBEA). We used 42 Wistar-Hannover rats, weighing
approximately 250g each, from the Veterinary Sciences Labo-
ratory of the Federal University of Piauí. Persistent estrus
was induced in the animals through a subcutaneous injection
of 1.25 mg of testosterone propionate on the second day of
life. During the study, all animals were housed in plastic
cages with metal tops (grills) at an ambient temperature
ranging from 20oC to 24oC. Fluorescent lamps provided
12-h light/12-h dark cycles. While their food portions were
rationed, the rats had free access to filtered water. At
90 days of life, androgenized rats were selected for research.
Persistent estrus rats presented with occlusion of the distal
third of the vagina and keratinization of the vaginal
epithelium (the main characteristic of persistent estrus); the
presence of polycystic ovaries was noted at the time of
autopsy (15). The animals were randomly divided into two
groups: group I (control, n=21) and group II (experimental,
n=21). Each rat from Group I (control) received 0.1 mL/day
of propylene glycol (vehicle) and each rat from experimental
group II received 0.5 mg/kg or 0.125 mg/day of anastrozole
diluted with 0.1 mL of propylene glycol (17). The vehicle and
anastrozole were administered by oral gavage continuously
for 28 days, at the same time of each day (between 15:00
and 16:00). On the 29th day, the rats from both groups were
euthanized by an intraperitoneal injection containing an
excessive dose of anesthetics, 300 mg/kg ketamine and
15 mg/kg midazolam. The rats were then immobilized on a
cork board to remove the vagina, and the tissue was fixed in
buffered formalin (pH approximately 7.5). After 24h fixation,
the vaginal epithelium was subjected to immunohistochem-
ical analysis.
Immunohistochemistry
Histological sectioning to produce the histological slides
was performed using the Minota-type microtome adjusted
to 5-mm thickness. The preparation of the histological slides
and respective immunohistochemistry, were performed
simultaneously under the same conditions. Immunohisto-
chemical evaluation of the Ki-67 marker was performed
using a detection system combined with an antigen retrieval
method. For this, the sections were treated with 3% hydro-
gen peroxide diluted in buffered solution for 5 min to block
the endogenous peroxide. Following antigen recovery, tissue
samples were incubated with anti-Ki-67 rat primary mono-
clonal antibody (clone MIB-5/1:100) for 16h overnight in a
refrigerator at approximately 4oC. The samples were then
washed with buffered saline and incubated for 45 min
with the New Link Polymer detection system. To read these
reactions, all histological slides were treated for 5 min with
a 3-3 solution of benzidine diamine tetrahydrochloride at a
concentration of 1 mg/mL of Tris buffered saline and hydro-
gen peroxide solution, then contrasted with Harris Hema-
toxylin for 5 min, followed by dehydration in ethyl alcohol
and xylol baths. The cells were considered positive for
immunohistochemical expression of the Ki-67 antigen when
their nuclei were stained with a brown color.
Quantitative method
Cell counting was performed manually by two blind
observers in relation to the groups studied, and the positive
and negative cells were labeled separately to avoid counting
the same cells more than once. Cell counting was performed
at a research laboratory located at the Gynecological Coordi-
nation of the Getulio Vargas Hospital/Federal University of
Piaui, where a computerized system consisting of a Light
Microscope Eclipse E-400 (Tokyo, Japan) was used, coupled
with a color camcorder (Samsung Digital Camera SCC-131,
Seoul, South Korea). Images were captured on a Pentium IV
microcomputer with an 80-Gigabyte hard drive, 3.0-GHz
processor, 1024 RAM, and graphics card using Windows XP.
Cell counting for Ki-67 positive and negative cells was
performed at 400 magnification. At least 500 cells in the
vaginal epithelium were counted in each slide in random
fields, starting in the area of higher nuclei concentration
with Ki-67 expression, using Imagelabs Image Analysis
and Processing Software (SOFTIUM Informática LTDA, São
Paulo, Brazil).
Statistical Analysis
The data were analyzed using the non-parametric Mann–
Whitney test. The data were tabulated using the IBM SPSS
Statistics V21 program, with the significance level set at
po0.05.
’ RESULTS
Under light microscopy, the concentration of cells expres-
sing the Ki-67 antigen was higher in the control group
compared to the experimental group (Figure 1). The mean
numbers (±standard error [SE] of the mean) of Ki-67-stained
nuclei in the vaginal epithelium of rats in persistent estrus
were 68.64±2.64 and 30.46±2.00 in groups I (control) and II
(experimental), respectively (po0.003) (Table 1). Figure 2
clearly shows the difference between the mean percentage
of Ki-67-stained nuclei in the control and experimental
groups.
’ DISCUSSION
Studies on the effects of drugs used to treat hormone-
sensitive breast cancer in human tissue are limited for ethical
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Figure 1 - Photomicrography of a histological section of the vaginal epithelium from a female rat in persistent estrus. Note the presence
of a higher concentration nuclei stained brown by anti-Ki-67 (MIB-5) antibody prior to treatment with anastrozole, control group (A),
and sparsely stained nuclei post-treatment, experimental group (B) (original magnification=400x).
Table 1 - Mean percentage of Ki-67 nuclei per 500 cells in the control an experimental groups.
% Ki-67-stained nuclei
Mean SE Median Minimum Maximum
Group Control 68.64 2.64 71.76 38.98 81.21
Experimental 30.46* 2.00 28.71 17.47 55.85
*There was a statistically significant decrease in Ki-67-stained nuclei after treatment with aanastrozole (po0.003).
Figure 2 - Box plot clearly showing the difference between the mean percentage of Ki-67 stained nuclei in the control and
experimental groups.
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reasons; hence experiments using animal models are reason-
able alternatives. This led us to study the effects of anastrozole,
an inhibitor of the synthesis of estrogens, in a rat experimental
model where the rats are in persistent estrus as the vaginal
epithelium is under constant estrogen stimulation. In the
present study, rats in persistent estrus (control) showed a
higher concentration of Ki-67-stained nuclei in the epithe-
lium compared to the group treated with anastrozole.
The mean number of Ki-67-stained nuclei was significantly
reduced in the group treated with anastrozole than in the
control group.
The persistent estrus female rat is an animal model that
mimics polycystic ovarian syndrome. The female rat in
persistent estrus an intensely proliferated vaginal epithelium
with vaginal cornification, a characteristic that defines this
experimental model (15). The persistent estrus female rat
animal model is an interesting model to study molecules
that inhibit the synthesis of estrogens, such as aromatase
inhibitors. Kubtka et al. (17) showed high tumor suppressive
effects of letrozole in a premenopausal model of mammary
carcinogenesis in female rats.
In this study, anastrozole was administered by oral gavage,
which, although more laborious, is similar to the route
commonly used by human females. In postmenopausal
women, anastrozole is generally administered at a dose of
1 mg/day for breast cancer treatment (6,19). However,
there are differences in drug absorption and metabolism
between humans and animals, since rats have a more rapid
metabolism (20). Considering these aspects, administration
by oral gavage allowed the animals to receive a selected
dose of drug more similar to that in humans (21). We
administered an anastrozole dose of 0.5 mg/kg per day or
0.125 mg/animal/day based on studies by Kubatka et al.
(22) and Sadlonova et al. (18), who observed that a dose of
0.5 mg/kg administered to rats is similar to a daily clinical
dose of 1 mg in postmenopausal women with breast cancer.
Some studies have evaluated cell proliferation in the
mammary, uterine, and vaginal epithelia of rats based on the
expression of the Ki-67 antigen. Gerdes et al. (23) found a
Ki-67 antibody that recognized a nuclear antigen present in
proliferating cells and absent in resting cells, making it ideal
for the evaluation of cell proliferative activity. Anastrozole is
administered in postmenopausal women with hormone-
sensitive breast cancer; however, it has been shown that
aromatase inhibitors may lead to adverse effects in pre-
menopausal female rats, such as dietary exemestane-induced
mammary carcinogenesis (24). Nevertheless, the effects of
anastrozole administered by oral gavage to premenopausal
rats, as opposed to oral exposure in the diet, are unknown.
Meanwhile, Nery-Aguiar et al. (1) administered tamoxifen to
castrated female rats, mimicking postmenopausal women,
which increased proliferation in the vaginal epithelium.
On the other hand, Sousa-Lages et al. (25) did not show
alterations in the vaginal epithelium of castrated female rats
with the use of pilocarpine, a cholinergic parasympathomi-
metic agonist that induces an increase in glandular secretion
and with controversial effects on vaginal dryness.
The few studies that do exist on the effects of aromatase
inhibitors in the uterine and vaginal epithelia of rats present
controversial results. Kubatka et al. (17) analyzed the pre-
ventative effects of letrozole in rats and found that letrozole
leads to uterine and vaginal atrophy, increased concentra-
tions of plasma triacylglycerols, and increased body weight.
In contrast to these results, in two other studies, Kubatka
et al. (22) analyzed the chemopreventive effects of anastro-
zole and showed that the drug suppressed breast tumor
incidence by 40%; however, its effects were not shown on the
genital system (uterus and vagina) of these rats. The same
authors analyzed the effects of exemestane on the histo-
pathology of the uterus and vagina; the study also did not
reveal alterations, which points to the non-antiestrogenic
effects of the drug (24). Sadlonova et al. (18) also analyzed
the effects of anastrozole; their histological examination did
not show atrophic changes in the endometrium of the uterus
and vaginal epithelia.
According to the aforementioned studies, the drugs were
administered in the animal feed, and as reported, letrozole
caused uterine and vaginal atrophy. These authors also
did not identify any vaginal alterations after administering
exemestane and anastrozole in the animal feed. On the other
hand, Barros-Oliveira et al. showed significantly decreased
expression of cell proliferation based on Ki-67 expression in
the mammary epithelium of rats in persistent estrus receiv-
ing 0.125 mg daily of anastrozole by oral gavage for 28 days
(20). Furthermore, Ferreira et al. (26) and Mahamed et al. (27)
showed a reduction in uterine cell apoptosis and endometrial
thickness of rats in persistent estrus treated with melatonin
and metformin, respectively.
Thus, we conclude that anastrozole administered to female
rats in persistent estrus at a dose of 0.5 mg/kg/day, that
is 0.125 mg/day, by oral gavage for 28 days, significantly
decreased Ki-67 antigen expression in the vaginal epithe-
lium, showing an anti-proliferative effect of anastrozole on
the vaginal mucosa. However, further studies are necessary
and important to confirm these scientific findings.
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